Sponsor: National Cancer Institute
Sponsor Study ID: 5P01CA203628
Study Title: A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients with Prostate Cancer Progression on Enzalutamide or Abiraterone
CTO #: 103193
NCT Number: NCT04207255
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Prostate
Study Objectives: This is a Phase II efficacy study of opaganib in patients with metastatic castration-resistant prostate cancer (mCRPC) that is progressing during treatment with androgen signaling blockers abiraterone or enzalutamide.